Endocrine and Metabolic Illnesses in Young Adults with Prader–Willi Syndrome

Prader–Willi syndrome (PWS) is a rare genetic disorder characterized by an insatiable appetite that leads to morbid obesity. Previous studies reported health problems in adults with PWS. However, studies on younger adults are lacking, and there are no specific studies of endocrine and metabolic illness in this age group. We performed a retrospective cohort study of 68 individuals with PWS aged 19 to 34 years at Samsung Medical Center. The prevalence of endocrine and metabolic illnesses were compared with those in an age-, sex-, and BMI-matched healthy control group. Young adults with PWS had a higher prevalence of metabolic syndrome (35.3% vs. 4.4%), type 2 diabetes mellitus (50.0% vs. 5.4%), hypertension (30.8% vs. 16.1%), dyslipidemia (38.2% vs. 14.7%), decreased bone density (26.4% vs. 0.9%), and sleep apnea (32.3% vs. 4.4%) than controls (all p < 0.05). The PWS group that maintained recombinant human growth (rhGH) treatment in adulthood had a lower probability of having a BMI ≥ 30 at the last follow-up (odds ratio = 0.106 (0.012–0.948), p = 0.045). Endocrine and metabolic illnesses in individuals with PWS may have already started in the early teens; therefore, appropriate screening and early intervention are important. Better understanding of the natural history of PWS and age-related complications will lead to better-quality medical care for individuals with PWS.

[1]  M. Butler,et al.  Central adrenal insufficiency screening with morning plasma cortisol and ACTH levels in Prader–Willi syndrome , 2022, Journal of pediatric endocrinology & metabolism : JPEM.

[2]  Joongbum Cho,et al.  Tailored management of life-threatening complications related to severe obesity in a young adult with Prader-Willi syndrome , 2021, Annals of pediatric endocrinology & metabolism.

[3]  Y. Lee,et al.  The effects of glucagon‐like peptide (GLP)‐1 receptor agonists on weight and glycaemic control in Prader–Willi syndrome: A systematic review , 2021, Clinical endocrinology.

[4]  M. Polak,et al.  Growth Hormone Treatment for Adults With Prader-Willi Syndrome: A Meta-Analysis , 2021, The Journal of clinical endocrinology and metabolism.

[5]  M. Szalecki,et al.  Comparison of Frequency and Severity of Sleep-Related Breathing Disorders in Children with Simple Obesity and Paediatric Patients with Prader–Willi Syndrome , 2021, Journal of personalized medicine.

[6]  M. Maghnie,et al.  Sleep disorders in Prader-Willi syndrome, evidence from animal models and humans. , 2021, Sleep medicine reviews.

[7]  A. J. van der Lely,et al.  Missed Diagnoses and Health Problems in Adults With Prader-Willi Syndrome: Recommendations for Screening and Treatment , 2020, The Journal of clinical endocrinology and metabolism.

[8]  E. Boss,et al.  Outcomes of Adenotonsillectomy for Obstructive Sleep Apnea in Prader‐Willi Syndrome: Systematic Review and Meta‐analysis , 2020, The Laryngoscope.

[9]  M. Polak,et al.  Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis , 2020, BMJ Paediatrics Open.

[10]  M. Coupaye,et al.  Central Adrenal Insufficiency Is Rare in Adults With Prader–Willi Syndrome , 2020, The Journal of clinical endocrinology and metabolism.

[11]  G. Parati,et al.  Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. , 2019, European journal of internal medicine.

[12]  Byung Jin Kim,et al.  2018 Guidelines for the Management of Dyslipidemia in Korea , 2019, The Korean journal of internal medicine.

[13]  Byung Jin Kim,et al.  2018 Guidelines for the Management of Dyslipidemia in Korea , 2019, Journal of lipid and atherosclerosis.

[14]  G. Muscogiuri,et al.  Prader- Willi syndrome: An uptodate on endocrine and metabolic complications , 2019, Reviews in Endocrine and Metabolic Disorders.

[15]  V. Kimonis,et al.  Contributing factors of mortality in Prader–Willi syndrome , 2019, American journal of medical genetics. Part A.

[16]  A. Hokken-Koelega,et al.  Bone mineral density in young adults with Prader‐Willi syndrome: A randomized, placebo‐controlled, crossover GH trial , 2018, Clinical endocrinology.

[17]  Jinsup Kim,et al.  Prevalence and risk factors for type 2 diabetes mellitus with Prader–Willi syndrome: a single center experience , 2017, Orphanet Journal of Rare Diseases.

[18]  J. Manson,et al.  Associations of Weight Gain From Early to Middle Adulthood With Major Health Outcomes Later in Life , 2017, JAMA.

[19]  S. Grottoli,et al.  Management of GH treatment in adult GH deficiency. , 2017, Best practice & research. Clinical endocrinology & metabolism.

[20]  M. Butler,et al.  Causes of Death in Prader-Willi Syndrome: Prader-Willi Syndrome Association (USA) 40-Year Mortality Survey , 2016, Genetics in Medicine.

[21]  K. Clément,et al.  Effect of Genotype and Previous GH Treatment on Adiposity in Adults With Prader-Willi Syndrome. , 2016, The Journal of clinical endocrinology and metabolism.

[22]  A. Salvatoni,et al.  Disorders of glucose metabolism in Prader-Willi syndrome: Results of a multicenter Italian cohort study. , 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[23]  G. Parati,et al.  Heart failure and sleep disorders , 2016, Nature Reviews Cardiology.

[24]  M. Butler,et al.  Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches. , 2016, Current pediatric reviews.

[25]  J. Jauregi,et al.  Medical, psychological and social features in a large cohort of adults with Prader-Willi syndrome: experience from a dedicated centre in France. , 2015, Journal of intellectual disability research : JIDR.

[26]  J. Emerick,et al.  Growth Hormone Therapy in Adults with Prader-Willi Syndrome , 2015, Diseases.

[27]  A. Salvatoni,et al.  Central adrenal insufficiency in young adults with Prader‐Willi Syndrome , 2013, Clinical endocrinology.

[28]  M. Polak,et al.  Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood. , 2013, The Journal of clinical endocrinology and metabolism.

[29]  A. Klibanski,et al.  Effects of recombinant human growth hormone therapy in adults with Prader–Willi syndrome: a meta‐analysis , 2012, Clinical endocrinology.

[30]  M. Davey,et al.  Longitudinal association between growth hormone therapy and obstructive sleep apnea in a child with Prader-Willi syndrome. , 2011, The Journal of clinical endocrinology and metabolism.

[31]  A. Belgorosky,et al.  Thyroid axis dysfunction in patients with Prader‐Willi syndrome during the first 2 years of life , 2010, Clinical endocrinology.

[32]  P. Vestergaard,et al.  Reduced bone mineral density and increased bone turnover in Prader-Willi syndrome compared with controls matched for sex and body mass index--a cross-sectional study. , 2004, The Journal of pediatrics.

[33]  Dong Ho Kim,et al.  Bone mineral density according to age, bone age, and pubertal stages in korean children and adolescents. , 2010, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.